Rob Maloney: What If Hemophilia No Longer Needed Lifelong Treatment?
Rob Maloney, Chief Executive Officer of Hemophilia of Georgia, shared a post on LinkedIn:
“I’ve said something a few times that usually gets a laugh, but I mean it.
I’d like to work myself out of a job.
Here’s what I mean. I would love to see the day when hemophilia treatment has advanced so far that what we currently build entire systems around becomes far less necessary.
A real cure.
Or something close to it.
Not just symptom management stretched out over a lifetime.
I think we could be closer than people realize.
And I want Hemophilia of Georgia to be part of helping push that future forward.
That means supporting research, advocating for investment in research, and helping connect our community to opportunities that advance care.
Right now, a lot of the innovation in healthcare still centers on managing chronic conditions, not eliminating them.
That may be practical. But as a mission-driven leader, I’m interested in something else.
What if the next decade could fundamentally change how a person with hemophilia lives?
What if families no longer had to choose where to live based on proximity to a treatment center?
What if a child in South Georgia could grow up without needing the same level of medical caution because the underlying condition had been changed at the root?
Even in a future with transformative therapies, families will still need education, advocacy, community, and support.
But the burdens they face could look very different than they do today.
I’m proud of the support systems we’ve built. I believe deeply in the work HoG does every day.
But if we can support the kind of research that makes our current model less necessary over time, then that’s not a threat to the mission.
That is the mission.
If leadership is stewardship, then part of my job is not just maintaining what we’ve inherited.
It’s helping build a future where families need less rescue and more freedom.”
Other posts featuring Rob Maloney on Hemostasis Today.
-
Sep 20, 2026, 13:29Factor XI Deficiency and the Challenge of Unpredictable Bleeding – EHC
-
Sep 20, 2026, 13:18Cindy Howry: FDA Approves First Treatment for Ataxia-Telangiectasia
-
Sep 20, 2026, 13:08Mohammad Salar Amoli: When Routine Coagulation Tests Miss von Willebrand Disease
-
Sep 20, 2026, 12:55Stelios Andreadis։ Human Salivary Gland Organoids Offer New Potential for Regenerative Medicine
-
Sep 20, 2026, 12:43Obi Light Ogbonnia: The Power of Lived Experience in Sickle Cell Care
-
Sep 20, 2026, 12:34Sabrine Mekni: Advancing HSCT for Children With Fanconi Anemia
-
Sep 20, 2026, 12:11Giacomo Buso: Silent Atherosclerosis Begins Earlier Than Expected
-
Sep 20, 2026, 12:0310 Posts Not to Miss This Week
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI